Status:
COMPLETED
Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia
Lead Sponsor:
Vanda Pharmaceuticals
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine the safety and efficacy of iloperidone compared to placebo and an active comparator in the treatment of patients with schizophrenia in acute exacerbation.
Detailed Description
Schizophrenia is a severe mental illness affecting an estimated 1% of the world's population. Patients with schizophrenia suffer from productive symptoms (e.g., hallucinations and delusions), and defi...
Eligibility Criteria
Inclusion
- DSM-IV diagnosis of schizophrenia
- PANSS-T of at least 70 at screening and baseline
Exclusion
- Clinically significant disease of the heart, kidneys, liver or gastrointestinal system
- DSM-IV diagnosis of psychiatric disorder other than schizophrenia
Key Trial Info
Start Date :
November 18 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 21 2007
Estimated Enrollment :
593 Patients enrolled
Trial Details
Trial ID
NCT00254202
Start Date
November 18 2005
End Date
March 21 2007
Last Update
December 13 2024
Active Locations (42)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanda Investigational Site
Little Rock, Arkansas, United States, 72211
2
Vanda Investigational Site
Anaheim, California, United States, 92805
3
Vanda Investigational Site
Cerritos, California, United States, 90703
4
Vanda Investigational Site
Garden Grove, California, United States, 92845